- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00745251
A Study of VI-0521 for the Treatment of Obstructive Sleep Apnea / Hypopnea Syndrome in Obese Adults
September 5, 2012 updated by: VIVUS LLC
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of VI-0521 for the Treatment of Obstructive Sleep Apnea / Hypopnea Syndrome in Obese Adults
The primary objectives of this study are to evaluate the safety and efficacy of VI-0521 compared to placebo in the treatment of obese adults with obstructive sleep apnea (OSA) and to assess the relative contributions of weight loss on parameters of OSA in these subjects.
Study Overview
Study Type
Interventional
Enrollment (Actual)
45
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Kentucky
-
Louisville, Kentucky, United States, 40217
- Kentucky Research Group
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
30 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Obese adults 30 - 65 years old (inclusive);
- Women of child-bearing potential must be using adequate contraception;
- BMI between 30 and 40 kg/m2 (inclusive);
- Diagnosis of OSA syndrome with Apnea/Hypopnea Index (AHI) of 15 or greater;
- Unwilling or unable to comply with CPAP treatment;
Exclusion Criteria:
- Known allergy or hypersensitivity to phentermine or topiramate;
- Sleep disorder other than OSA syndrome;
- Women who are pregnant, breast feeding, or intend to become pregnant during the study;
- Presence of unstable angina or heart failure corresponding to NYHA functional class III or IV;
- History of myocardial infarction or coronary revascularization within the past year; any history of stroke;
- Presence of any clinically significant abnormality on electrocardiogram;
- Use of any prescription CNS stimulants;
- History of cholecystitis or cholelithiasis unless treated by cholecystectomy;
- History of glaucoma or any past or present use of medications to treat increased intraocular pressure;
- Weight gain or loss of greater than 5 kg, use of a very low-calorie diet, or participation in a formal weight loss program (investigational or otherwise) within the past 3 months;
- Previous bariatric surgery;
- Shift workers or any subjects with a circadian rhythm disorder;
- Professional drivers or commercial pilots;
- History of nephrolithiasis;
- More than one lifetime episode of major depression;
- History of bipolar disorder, obsessive compulsive disorder, borderline personality disorder, psychotic depression, schizophrenia, schizoaffective disorder, or any other psychotic disorder; history of any psychiatric hospitalization;
- History of a seizure disorder; concurrent use of any anticonvulsant drug (other than assigned study drug);
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
placebo
|
Experimental: VI-0521
15 mg Phentermine and 92 mg Topiramate
|
15 mg Phentermine and 92 mg Topiramate
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in the Apnea/Hypopnea Index (AHI) Between Baseline and Week 28/Early Term.
Time Frame: between baseline and Week 28
|
AHI is calculated as the mean number of apnea or hypopnea episodes (each lasting a minimum of 10 second) observed per hour of sleep
|
between baseline and Week 28
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percent Change in Weight From Baseline to Week 28
Time Frame: baseline to week 28
|
baseline to week 28
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Charles Bowden, MD, VIVUS LLC
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2008
Primary Completion (Actual)
September 1, 2009
Study Completion (Actual)
December 1, 2009
Study Registration Dates
First Submitted
August 31, 2008
First Submitted That Met QC Criteria
August 31, 2008
First Posted (Estimate)
September 3, 2008
Study Record Updates
Last Update Posted (Estimate)
October 5, 2012
Last Update Submitted That Met QC Criteria
September 5, 2012
Last Verified
September 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- OB-204
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sleep Apnea
-
ResMedCRI-The Clinical Research Institute GmbH; University Hospital RegensburgCompletedObstructive Sleep Apnea | Central Sleep Apnea | Mixed Sleep Apnea | Complex Sleep ApneaSwitzerland, Spain, Denmark, Portugal, France, Germany
-
ResMedCompletedObstructive Sleep Apnea | Central Sleep Apnea (Diagnosis) | Chronic Opioid UseUnited States
-
ResMedRWTH Aachen UniversityRecruitingObstructive Sleep Apnea | Central Sleep Apnea | Mixed Sleep ApneaGermany
-
Somnarus IncCompletedObstructive Sleep Apnea | Cheyne-Stokes Respiration | Central Sleep Apnea | Mixed Sleep ApneaUnited States
-
Medtronic - MITGCompletedObstructive Sleep Apnea | Sleep Apnea | Sleep-Disordered Breathing | Central Sleep ApneaUnited States
-
University of California, Los AngelesRecruiting
-
Brigham and Women's HospitalCompletedObstructive Sleep Apnea (OSA)United States
-
LivaNovaRecruitingApnea | Obstructive Sleep Apnea | OSA | Apnea, Obstructive | Apnea+Hypopnea | Apnea, Obstructive Sleep | Hypopnea, SleepUnited States
-
The Hospital for Sick ChildrenRecruitingObstructive Sleep Apnea | Hypoventilation | Central Sleep ApneaCanada
-
Cleveland Medical Devices IncJohns Hopkins University; The Cleveland Clinic; National Institutes of Health...CompletedObstructive Sleep Apnea | Sleep Disordered Breathing | Central Sleep ApneaUnited States
Clinical Trials on placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States